Sort
30,917 grants matching “tumor microenvironment”
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade
$393,450Amer Aziz Beg · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2017 · CA
Defining the Roles of Bone Marrow Adipocytes and FABP4/5 Signaling in Multiple Myeloma Drug Resistance
$393,450Michaela R. Reagan · Mainehealth · R37 · FY2022 · CA
Defining the Roles of Bone Marrow Adipocytes and FABP4/5 Signaling in Multiple Myeloma Drug Resistance
$393,450Michaela R. Reagan · Mainehealth · R37 · FY2021 · CA
Defining the Roles of Bone Marrow Adipocytes and FABP4/5 Signaling in Multiple Myeloma Drug Resistance
$393,450Michaela R. Reagan · Mainehealth · R37 · FY2020 · CA
Regulation of dendritic cell function and tumor immunity by TIM-3
$393,450Brian Ruffell · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · CA
Regulation of dendritic cell function and tumor immunity by TIM-3
$393,450Brian Ruffell · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2021 · CA
Regulation of dendritic cell function and tumor immunity by TIM-3
$393,450Brian Ruffell · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2020 · CA
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade
$393,450Amer Aziz Beg · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2020 · CA
INTEGRIN SIGNALING DURING BREAST TUMORIGENESIS
$393,420Filippo G Giancotti · Sloan-Kettering Inst Can Research · R01 · FY2009 · CA
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
$393,420Renier Joseph Brentjens · Sloan-Kettering Inst Can Research · R01 · FY2009 · CA
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
$393,420Renier Joseph Brentjens · Sloan-Kettering Inst Can Research · R01 · FY2010 · CA
Leveraging cancer-evolved resistance mechanisms to enhance EZH2 activity in adoptive T cells
$393,401Alan Jackson Tackett · Univ Of Arkansas For Med Scis · R21 · FY2024 · CA
PROTACs for pancreatic cancer therapy
$393,400Amarnath Natarajan · University Of Nebraska Medical Center · R21 · FY2020 · CA
The Inhibition of HNSCC Growth and Metastasis by Targeting KDM4A
$393,397Cun-Yu Wang · University Of California Los Angeles · R01 · FY2022 · DE
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines
$393,352Jonathan F Lovell · State University Of New York At Buffalo · R01 · FY2020 · CA
Measuring extracellular pH in pre-clinical tumor models with CEST MRI
$393,301Mark David Pagel · University Of Arizona · R01 · FY2015 · CA
Brain Tumor Immunotherapy
$393,294Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Project 5 - EBV Drivers of Oncogenesis and Novel Therapies
$393,288Shannon Celeste Kenney · University Of Wisconsin-Madison · P01 · FY2020 · CA
Project 5 - EBV Drivers of Oncogenesis and Novel Therapies
$393,288Shannon Celeste Kenney · University Of Wisconsin-Madison · P01 · FY2018 · CA
Targeting ovarian cancer spheroid formation and metabolic adaptation by APJ inhibition
$393,267Sukyung Woo · State University Of New York At Buffalo · R01 · FY2025 · CA
Engineering Nanomaterials to Prime Immunity
$393,246James J. Moon · University Of Michigan At Ann Arbor · R01 · FY2017 · CA
Shifting the balance between IFN-I and TGF-beta to improve cancer therapy
$393,225Mark W Jackson · Cleveland Clinic Lerner Com-Cwru · P01 · FY2023 · CA
Mechanisms of secondary injury after SCI
$393,185Michael S. Beattie · University Of California, San Francisco · R01 · FY2015 · NS
Project 3: Identifying and targeting mediators of CNS metastasis from lung cancer
$393,173Don X Nguyen · Yale University · P50 · FY2024 · CA
Specialized Niches for Pediatric Astrocytoma Cells
$393,161Rosalind A Segal · Dana-Farber Cancer Inst · P01 · FY2015 · CA